Presbyopia-correcting IOLs they way to go?

Article

I am not convinced that using two very different types of lenses in one patient is the best way to maximize the visual system

Since our practice began offering presbyopia-correcting intraocular lenses (IOLs), we have implanted around 450 of them. One in five of our cataract and refractive lens exchange patients now chooses one of these new lenses. The AcrySof ReSTOR lens (Alcon Laboratories) accounts for 80% of our presbyopia-correcting implants, while the ReZoom (AMO) and the crystalens (eyeonics) together represent 20%.

Establish the needs of the patient

Think carefully before mixing and matching

Our results confirm this. Patients who have received the ReSTOR lenses have excellent near and distance vision and their intermediate vision is better than I had anticipated. By tracking satisfaction among patients who received bilateral ReSTOR lenses and remain in our care after surgery, we have learned that 90% never wear glasses; 100% have better than 20/40 uncorrected distance vision; and 90% see J3 or better at near. In addition, patients who use computers do better with ReSTOR lenses than has been reported. Furthermore, patients are generally satisfied with their first ReSTOR implant, but are happiest once they receive their second one. We do find these patients may need a little more light for their intermediate distance viewing, but generally they function very well under normal lighting conditions.

Recent Videos
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Abdelrahman Elhusseiny, MD, MSc, discusses his AAO presentation on risk of posterior capsular rupture in fellow-eyes cataract surgery
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
Marjorie Rah, OD, PhD, FAAO
Josefina Botta, MD, MSc, at ASCRS 2024
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
© 2024 MJH Life Sciences

All rights reserved.